A panelist discusses how real-world evidence from a large cohort study (n = 31521) presented at AAD 2025 reveals notable differences in treatment patterns, discontinuation rates, persistence, and adherence among psoriasis patients treated with different biologics including tildrakizumab, risankizumab, guselkumab, and ustekinumab, with implications for clinical decision-making based on early versus late disease onset and prior biologic exposure.
Knowledge Gaps Persist in Patient Understanding of Skin Cancer–Related Terms
January 13th 2026On average, patients with multiple prior dermatology visits still scored below 75% when identifying common skin cancer terms, underscoring the need for clearer patient-physician communication.
Read More